

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (Canceled)

Claim 22 (Previously Presented): The method of claim 30 wherein the animal is a human.

Claims 23-24 (Cancelled)

Claim 25 (Previously Presented): The method of claim 32, wherein said animal has Type 2 diabetes.

Claim 26 (Previously Presented): The method of claim 29 wherein said animal is obese.

Claims 27-28. (Cancelled)

Claim 29 (Previously Presented): A method of decreasing blood glucose levels in an animal comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 30 (Original): The method of claim 29 wherein the animal is a human or a rodent.

Claim 31 (Original): The method of claim 29 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 32 (Original): The method of claim 29 wherein the animal is a diabetic animal.

Claims 33-36 (Canceled).

Claim 37 (Currently Amended): A method of ~~preventing~~ ~~or~~ delaying the onset of an increase in blood glucose levels in an animal comprising administering to said animal with Type 2 diabetes a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 38 (Currently Amended): A method of ~~preventing~~ ~~or~~ delaying the onset of an increase in blood glucose levels in an obese animal comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claims 39-40 (Canceled).

Claim 41(Previously Presented): A method of delaying the onset of an increase in blood glucose levels in an animal comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 42(Original): The method of claim 41 wherein the animal is a human or a rodent.

Claim 43(Original): The method of claim 41 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 44(Original): The method of claim 41 wherein the animal is a diabetic animal.

Claim 45(Previously Presented): A method of lowering plasma insulin levels in an animal comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 46(Previously Presented): The method of claim 45 wherein said animal is a non- human primate or human.

Claim 47(Previously Presented): A method of increasing insulin sensitivity in an animal comprising

administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 48 (Canceled)

Claim 49 (Previously Presented): A method of treating, or delaying the onset of, Type 2 diabetes in an animal comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 50 (Canceled)

Claim 51 (New). The method of claim 37 wherein the animal is a human or a rodent.

Claim 52 (New). The method of claim 51 wherein the animal is a human.

Claim 53 (New). The method of claim 37 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 54 (New). The method of claim 37 wherein said animal is obese.

Claim 55(New). The method of claim 38 wherein the animal is a human or a rodent.

Claim 56(New). The method of claim 55 wherein the animal is a human.

Claim 57(New). The method of claim 38 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 58(New). The method of claim 38 wherein the animal is a diabetic animal.

Claim 59(New). The method of claim 58 wherein said animal has Type 2 diabetes.

Claim 60(New). The method of claim 42 wherein the animal is a human.

Claim 61(New). The method of claim 44 wherein said animal has Type 2 diabetes.

Claim 62(New). The method of claim 41 wherein said animal is obese.

Claim 63(New). The method of claim 46 wherein the animal is a human.

Claim 64(New). The method of claim 45 wherein the animal is a diabetic animal.

Claim 65(New). The method of claim 64 wherein said animal has Type 2 diabetes.

Claim 66(New). The method of claim 45 wherein said animal is obese.

Claim 67(New). The method of claim 47 wherein the animal is a human or a rodent.

Claim 68(New). The method of claim 67 wherein the animal is a human.

Claim 69(New). The method of claim 47 wherein the animal is a diabetic animal.

Claim 70(New). The method of claim 69 wherein said animal has Type 2 diabetes.

Claim 71(New). The method of claim 47 wherein said animal is obese.

Claim 72(New). The method of claim 49 wherein the animal is a human or a rodent.

Claim 73(New). The method of claim 72 wherein the animal is a human.

Claim 74(New). The method of claim 49 wherein said animal is obese.